FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1495686951> ?p ?o ?g. }

• W1495686951 endingPage "183" @default.
• W1495686951 startingPage "173" @default.
• W1495686951 abstract "Cystic fibrosis (CF) is a lethal, recessive, genetic disease affecting approximately 1 in 2500 live births among Caucasians. The CF gene codes for a cAMP/PKA-dependent, ATP-requiring, membrane chloride ion channel, generally found in the apical membranes of many secreting epithelia and known as CFTR (cystic fibrosis transmembrane conductance regulator). There are currently over 1700 known mutations affecting CFTR, many of which give rise to a disease phenotype. Around 75% of CF alleles contain the ΔF508 mutation in which a triplet codon has been lost, leading to a missing phenylalanine at position 508 in the protein. This altered protein fails to be trafficked to the correct location in the cell and is generally destroyed by the proteasome. The small amount that does reach the correct location functions poorly. Clearly the cohort of patients with at least one ΔF508 allele are a major target for therapeutic intervention. It is now over two decades since the CF gene was discovered and during this time the properties of CFTR have been intensely investigated. At long last there appears to be progress with the pharmaco-therapeutic approach. Ongoing clinical trials have produced fascinating results in which clinical benefit appears to have been achieved. To arrive at this point ingenious ways have been devised to screen very large chemical libraries for one of two properties: (i) agents promoting trafficking of mutant CFTR to, and insertion into the membrane, and known as correctors or (ii) agents which activate appropriately located mutant CFTR, known as potentiators. The best compounds emerging from these programmes are then used as chemical scaffolds to synthesize other compounds with appropriate pharmaceutical properties, hopefully with their pharmacological activity maintained or even enhanced. In summary, this approach attempts to make the mutant CFTR function in place of the real CFTR. A major function of CFTR in healthy airways is to maintain an adequate airway surface liquid (ASL) layer. In CF the position is further confounded since epithelial sodium channels (ENaC) are no longer regulated and transport salt and water out of the airways to exacerbate the lack of ASL. Thus an additional possibility for treatment of CF is to use agents that inhibit ENaC either alone or as adjuncts to CFTR correctors and/or potentiators. Yet a further way in which a pharmacological approach to CF can be considered is to recruit alternative chloride channels, such as calcium-activated chloride channel (CaCC), to act as surrogates for CFTR. A number of P2Y(2) receptor agonists have been investigated that operate by increasing Ca(2+)(i) which in turn activates CaCC. Some of these compounds are currently in clinical trials. The knowledge base surrounding the structure and function of CFTR that has accumulated in the last 20 years is impressive. Translational research feeding from this is now yielding compounds that provide real prospects for a pharmacotherapy for this disease." @default.
• W1495686951 created "2016-06-24" @default.
• W1495686951 creator A5026051372 @default.
• W1495686951 date "2011-04-06" @default.
• W1495686951 modified "2023-10-06" @default.
• W1495686951 title "New horizons in the treatment of cystic fibrosis" @default.
• W1495686951 cites W1516227220 @default.
• W1495686951 cites W1564267641 @default.
• W1495686951 cites W1820962178 @default.
• W1495686951 cites W1897443070 @default.
• W1495686951 cites W1900298576 @default.
• W1495686951 cites W1969273529 @default.
• W1495686951 cites W1976507289 @default.
• W1495686951 cites W1990573320 @default.
• W1495686951 cites W199462078 @default.
• W1495686951 cites W2003955042 @default.
• W1495686951 cites W2013782505 @default.
• W1495686951 cites W2021521740 @default.
• W1495686951 cites W2022634662 @default.
• W1495686951 cites W2022941489 @default.
• W1495686951 cites W2024357549 @default.
• W1495686951 cites W2032482731 @default.
• W1495686951 cites W2035131077 @default.
• W1495686951 cites W2037145532 @default.
• W1495686951 cites W2039599894 @default.
• W1495686951 cites W2053151480 @default.
• W1495686951 cites W2056626899 @default.
• W1495686951 cites W2062470622 @default.
• W1495686951 cites W2065152952 @default.
• W1495686951 cites W2071226544 @default.
• W1495686951 cites W2071954761 @default.
• W1495686951 cites W2072415775 @default.
• W1495686951 cites W2076739918 @default.
• W1495686951 cites W2079234445 @default.
• W1495686951 cites W2080047685 @default.
• W1495686951 cites W2083506368 @default.
• W1495686951 cites W2084725128 @default.
• W1495686951 cites W2085633946 @default.
• W1495686951 cites W2085700147 @default.
• W1495686951 cites W2087044311 @default.
• W1495686951 cites W2087645353 @default.
• W1495686951 cites W2088609483 @default.
• W1495686951 cites W2094398863 @default.
• W1495686951 cites W2096405956 @default.
• W1495686951 cites W2096580943 @default.
• W1495686951 cites W2096816858 @default.
• W1495686951 cites W2103043501 @default.
• W1495686951 cites W2112283435 @default.
• W1495686951 cites W2114567997 @default.
• W1495686951 cites W2115068668 @default.
• W1495686951 cites W2115253521 @default.
• W1495686951 cites W2116885714 @default.
• W1495686951 cites W2118823673 @default.
• W1495686951 cites W2125460059 @default.
• W1495686951 cites W2128730598 @default.
• W1495686951 cites W2128984788 @default.
• W1495686951 cites W2129121070 @default.
• W1495686951 cites W2131295433 @default.
• W1495686951 cites W2132665778 @default.
• W1495686951 cites W2144724313 @default.
• W1495686951 cites W2145346414 @default.
• W1495686951 cites W2150908316 @default.
• W1495686951 cites W2151770768 @default.
• W1495686951 cites W2156445984 @default.
• W1495686951 cites W2158010208 @default.
• W1495686951 cites W2163086904 @default.
• W1495686951 cites W2171619939 @default.
• W1495686951 cites W2181923630 @default.
• W1495686951 cites W2182029699 @default.
• W1495686951 cites W2183687504 @default.
• W1495686951 cites W2317516580 @default.
• W1495686951 cites W2338243080 @default.
• W1495686951 cites W270374260 @default.
• W1495686951 doi "https://doi.org/10.1111/j.1476-5381.2010.01137.x" @default.
• W1495686951 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3085876" @default.
• W1495686951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21108631" @default.
• W1495686951 hasPublicationYear "2011" @default.
• W1495686951 type Work @default.
• W1495686951 sameAs 1495686951 @default.
• W1495686951 citedByCount "57" @default.
• W1495686951 countsByYear W14956869512012 @default.
• W1495686951 countsByYear W14956869512013 @default.
• W1495686951 countsByYear W14956869512014 @default.
• W1495686951 countsByYear W14956869512015 @default.
• W1495686951 countsByYear W14956869512016 @default.
• W1495686951 countsByYear W14956869512017 @default.
• W1495686951 countsByYear W14956869512018 @default.
• W1495686951 countsByYear W14956869512019 @default.
• W1495686951 countsByYear W14956869512020 @default.
• W1495686951 countsByYear W14956869512021 @default.
• W1495686951 countsByYear W14956869512022 @default.
• W1495686951 countsByYear W14956869512023 @default.
• W1495686951 crossrefType "journal-article" @default.
• W1495686951 hasAuthorship W1495686951A5026051372 @default.
• W1495686951 hasBestOaLocation W14956869512 @default.
• W1495686951 hasConcept C104317684 @default.
• W1495686951 hasConcept C127716648 @default.
• W1495686951 hasConcept C143065580 @default.

• next